SAFETY DATA SHEET



SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Trade name or designation

of the mixture

LISKONUM TABLETS

Registration number

LISKONUM CONTROLLED RELEASE TABLETS 450 MG * ESKALITH CONTROLLED RELEASE **Synonyms**

TABLETS 450 MG * QUILONUM SR TABLETS * QUILONUM 450 MG SR TABLETS *

QUILONIUM-R TABLETS * LITHIUM CARBONATE, FORMULATED PRODUCT

Issue date 04-November-2014

Version number

04-November-2014 **Revision date**

1.2. Relevant identified uses of the substance or mixture and uses advised against

Identified uses Medicinal Product.

> This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant

to medicinal use of the product. In this instance patients should consult prescribing

information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate

safety data sheet for each ingredient.

Uses advised against No other uses are advised.

1.3. Details of the supplier of the safety data sheet

GlaxoSmithKline UK 980 Great West Road

Brentford, Middlesex TW8 9GS UK

UK General Information (normal business hours): +44-20-8047-5000

Email Address: msds@gsk.com Website: www.gsk.com

1.4. Emergency telephone

number

TRANSPORT EMERGENCIES::

UK In-country toll call: +(44)-870-8200418 International toll call: +1 703 527 3887

available 24 hrs/7 days; multi-language response

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

Classification according to Directive 67/548/EEC or 1999/45/EC as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Classification according to Regulation (EC) No 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

2.2. Label elements

Label according to Regulation (EC) No. 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Caution - Pharmaceutical agent. See section 11 for additional information on health hazards. 2.3. Other hazards

SECTION 3: Composition/information on ingredients

3.2. Mixtures

4365 Version #: 14 Revision date: 04-November-2014 Issue date: 04-November-2014

General information

CAS-No. / EC No. REACH Registration No. INDEX No. **Chemical name** % **Notes**

LITHIUM CARBONATE < 65 554-13-2

209-062-5

Classification: DSD: Repr. Cat. 1;R61, Xn;R22, Xi;R36, R64

> CLP: Acute Tox. 4;H302, Eye Irrit. 2;H319, STOT SE 3;H335, Repr. 1A;H360FD

POVIDONE 30 < 15 9003-39-8

Classification: **DSD**: R52/53

CLP: Aquatic Chronic 3;H412

Talc < 10 14807-96-6

238-877-9

Classification: DSD: -

CLP: -

13463-67-7 Titanium dioxide < 0.25

236-675-5

Classification: DSD: -

CLP:

Other components below reportable levels

List of abbreviations and symbols that may be used above

CLP: Regulation No. 1272/2008.

DSD: Directive 67/548/EEC.

M: M-factor

vPvB: very persistent and very bioaccumulative substance.

PBT: persistent, bioaccumulative and toxic substance.

#: This substance has been assigned Community workplace exposure limit(s).

Composition comments The full text for all R- and H-phrases is displayed in section 16.

SECTION 4: First aid measures

General information In the case of accident or if you feel unwell, seek medical advice immediately (show the label

where possible). Ensure that medical personnel are aware of the material(s) involved, and take

precautions to protect themselves.

4.1. Description of first aid measures

Inhalation Move to fresh air. If breathing is difficult, trained personnel should give oxygen. Call a physician if

symptoms develop or persist. Under normal conditions of intended use, this material is not

expected to be an inhalation hazard.

Skin contact Immediately flush skin with plenty of water. Take off contaminated clothing and wash before reuse.

Get medical attention if symptoms occur.

Eye contact Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.

Ingestion If swallowed, rinse mouth with water (only if the person is conscious). If ingestion of a large

Water. Foam. Dry chemical powder. Carbon dioxide (CO2).

amount does occur, call a poison control centre immediately. Do not induce vomiting without

advice from poison control center.

4.2. Most important symptoms and effects, both acute and

delayed

Direct contact with eyes may cause temporary irritation. Symptoms may include stinging, tearing, redness, swelling, and blurred vision. The following adverse effects have been noted with therapeutic use of this material: anorexia; dry mouth; nausea; vomiting; diarrhoea; tremor; thirst;

mental impairment.

4.3. Indication of any immediate medical attention and special treatment needed No specific antidotes are recommended. Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre.

SECTION 5: Firefighting measures

General fire hazards No unusual fire or explosion hazards noted.

5.1. Extinguishing media

media

Unsuitable extinguishing None known.

media

Material name: LISKONUM TABLETS

Suitable extinguishing

5.2. Special hazards arising from the substance or mixture During fire, gases hazardous to health may be formed.

5.3. Advice for firefighters

Special protective equipment for firefighters Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Special fire fighting

procedures

Move containers from fire area if you can do so without risk.

Specific methods Use standard firefighting procedures and consider the hazards of other involved materials.

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

Keep unnecessary personnel away. Keep people away from and upwind of spill/leak. Keep out of low areas. Wear appropriate protective equipment and clothing during clean-up. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Ensure adequate ventilation. Local authorities should be advised if significant spillages cannot be contained. For personal protection, see section 8.

For emergency responders

Keep unnecessary personnel away. Use personal protection recommended in Section 8 of the SDS.

6.2. Environmental precautions

Avoid discharge into drains, water courses or onto the ground.

6.3. Methods and material for containment and cleaning up Stop the flow of material, if this is without risk. Prevent entry into waterways, sewer, basements or

confined areas. Following product recovery, flush area with water.

6.4. Reference to other sections

For personal protection, see section 8. For waste disposal, see section 13 of the SDS.

SECTION 7: Handling and storage

7.1. Precautions for safe handling

Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Avoid contact with eyes. Avoid prolonged exposure. Do not taste or swallow. When using, do not eat, drink or smoke. Pregnant or breastfeeding women must not handle this product. Should be handled in closed systems, if possible. Provide adequate ventilation. Wear appropriate personal protective equipment. Wash hands thoroughly after handling. Observe good industrial hygiene practices.

7.2. Conditions for safe storage, including any incompatibilities

Store locked up. Store in original tightly closed container. Store away from incompatible materials (see Section 10 of the SDS).

7.3. Specific end use(s) Medicinal Product.

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

Occupational exposure limits

GSK Components	Туре	Value	Note
LITHIUM CARBONATE (CAS 554-13-2)	8 HR TWA	400 mcg/m3	
	OHC	2	Reproductive hazard
UK. EH40 Workplace Exp	osure Limits (WELs)		
Components	Туре	Value	Form
MAIZE STARCH (CAS 9005-25-8)	TWA	4 mg/m3	Respirable.
,		10 mg/m3	Inhalable
Talc (CAS 14807-96-6)	TWA	1 mg/m3	Respirable dust.
Titanium dioxide (CAS 13463-67-7)	TWA	4 mg/m3	Respirable.
,		10 mg/m3	Inhalable
ogical limit values	No biological exposure limits noted for the ingredient(s).		

Biol

Recommended monitoring

Derived no-effect level (DNEL)

procedures

Follow standard monitoring procedures.

Predicted no effect

Not available.

concentrations (PNECs)

Not available.

Exposure guidelines

8.2. Exposure controls

Material name: LISKONUM TABLETS

4365 Version #: 14 Revision date: 04-November-2014 Issue date: 04-November-2014

Appropriate engineering

controls

An Exposure Control Approach (ECA) is established for operations involving this material based upon the OEL/Occupational Hazard Category and the outcome of a site- or operation-specific risk

assessment. General ventilation normally adequate.

Individual protection measures, such as personal protective equipment

General information Personal protection equipment should be chosen according to the CEN standards and in

discussion with the supplier of the personal protective equipment. Follow all local regulations if

personal protective equipment (PPE) is used in the workplace.

If contact is likely, safety glasses with side shields are recommended. (e.g. EN 166). Not normally Eye/face protection

needed.

Skin protection

For prolonged or repeated skin contact use suitable protective gloves. Select suitable chemical - Hand protection

resistant protective gloves (EN 374) with a protective index 6 (>480min permeation time). Not

normally needed.

Wear suitable protective clothing as protection against splashing or contamination. (EN 14605 for - Other

splashes, EN ISO 13982 for dust). Not normally needed.

When workers are facing concentrations above the exposure limit they must use appropriate Respiratory protection

> certified respirators. Where breathable aerosols/dust are formed, use suitable combination filter for gases/vapours of organic, inorganic, acid inorganic, alkaline compounds and toxic particles (eg.

EN 14387). No personal respiratory protective equipment normally required.

Thermal hazards Wear appropriate thermal protective clothing, when necessary.

Always observe good personal hygiene measures, such as washing after handling the material Hygiene measures

and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants. For advice on suitable monitoring methods, seek guidance

from a qualified environment, health and safety professional.

Environmental exposure controls

Hazard guidance and control recommendations Environmental manager must be informed of all major releases.

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Appearance

Physical state Solid. **Form** Tablet

Colour Not available. Odour Not available. **Odour threshold** Not available. Not available.

pН Melting point/freezing point Initial boiling point and boiling

Not available.

range

Not available.

Not available. Flash point Not available. **Evaporation rate** Flammability (solid, gas) Not available. Upper/lower flammability or explosive limits

Flammability limit - lower

Not available.

(%)

Flammability limit - upper

Not available.

(%)

Vapour pressure Not available. Not available. Vapour density Not available. Relative density

Solubility(ies)

Not available. Solubility (water) Not available. Solubility (other) Partition coefficient Not available.

(n-octanol/water)

Not available. Not available.

Auto-ignition temperature Decomposition temperature Not available. Viscosity

Explosive propertiesNot available. **Oxidizing properties**Not available.

9.2. Other information No relevant additional information available.

SECTION 10: Stability and reactivity

10.1. ReactivityThe product is stable and non-reactive under normal conditions of use, storage and transport.

10.2. Chemical stability Material is stable under normal conditions.

10.3. Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

10.4. Conditions to avoidContact with incompatible materials.

10.5. Incompatible materials Peroxides. Phenols.

10.6. Hazardous None known. Irritating and/or toxic fumes and gases may be emitted upon the product's

decomposition products decomposition.

SECTION 11: Toxicological information

General information Occupational exposure to the substance or mixture may cause adverse effects.

Information on likely routes of exposure

Inhalation Under normal conditions of intended use, this material is not expected to be an inhalation hazard.

Skin contact Health injuries are not known or expected under normal use.

Eye contact Health injuries are not known or expected under normal use. Direct contact with eyes may cause

temporary irritation.

Ingestion Health injuries are not known or expected under normal use. Harmful if swallowed. However,

ingestion is not likely to be a primary route of occupational exposure.

Symptoms Direct contact with eyes may cause temporary irritation. Exposed may experience eye tearing,

redness, and discomfort.

The following adverse effects have been noted with therapeutic use of this material: anorexia; dry

mouth; nausea; vomiting; diarrhoea; tremor; thirst; mental impairment.

11.1. Information on toxicological effects

Acute toxicity Harmful if swallowed. Expected to be a low hazard for usual industrial or commercial handling by

trained personnel.

Components Species Test results

LITHIUM CARBONATE (CAS 554-13-2)

Acute

Inhalation

Human >= 1 mg/m3 Respiratory irritation

Oral

LD50 Rat 600 mg/kg

POVIDONE 30 (CAS 9003-39-8)

Acute

Oral

LD50

Rat > 5000 mg/kg

Titanium dioxide (CAS 13463-67-7)

Acute

Inhalation

LC50 Rat 6820 mcg/m3

Oral

LD50 Rat > 24 g/kg

Chronic

Inhalation

LOEC Rat 8.6 mg/m3, 1 years TiO2 accumulated in

interstitial macrophages, aggregated interstitial cells and particle laden macrophrages in lymphoid tissue.

NOAEC Rat 250 mg/m3, 2 years Highest dose

5 mg/m3, 24 months

Material name: LISKONUM TABLETS

SDS UK

4365 Version #: 14 Revision date: 04-November-2014 Issue date: 04-November-2014

Components **Species Test results Subacute** Inhalation LOEL Rat 0.1 - 35 mg/m3, 4 weeks Mild macrophage hyperplasia, no change in bronchio-alveolar lavage fluid. **NOAEC** 26 mg/m3, 3 weeks No evidence of Guinea pig significant inflammation in respiratory tract. Oral **NOAEL** Rat 100000 ppm, 14 Day Dietary study, highest dose tested. **Subchronic** Inhalation LOEC Rat 3.2 - 20 mg/m3, 8 min Accumulation of TiO2 in macrophages and evidence of pulmonary inflammation.

Skin corrosion/irritation

Health injuries are not known or expected under normal use.

Irritation Corrosion - Skin

TITANIUM DIOXIDE 0, Literature data

> Result: Non-irritant Species: Guinea pig 0, Literature data Result: Non-irritant Species: Human

Acute dermal irritation; OECD 404, Literature data

Result: Non-irritant Species: Rabbit

Serious eye damage/eye

irritation

Health injuries are not known or expected under normal use. Direct contact with eyes may cause

temporary irritation.

Eye

OECD 405 LITHIUM CARBONATE

Result: Irritant Species: Rabbit

Notes: Literature Reference TITANIUM DIOXIDE OECD 405, Literature data

> Result: Mild irritant Species: Rabbit

Respiratory sensitisation

None known.

Skin sensitisation

None known. This product is not expected to cause skin sensitisation.

Sensitisation

TITANIUM DIOXIDE

5 % Optimisation Test, Literature data - Vehicle: petrolatum

Result: negative Species: Guinea pig

Test Duration: 48 hour exposure Patch test, Literature data

Result: negative Species: Human

Germ cell mutagenicity

No data available to indicate product or any components present at greater than 0.1% are

mutagenic or genotoxic.

Mutagenicity

TITANIUM DIOXIDE

Ames, Literature data

Result: negative

Micronucleus Assay in vitro, CHO cells, Literature data

Result: negative

Micronucleus Assay in vitro, cultured human peripheral

lymphocytes, Literature data

Result: positive

Syrian Hamster Embryo (SHE) cell transformation assay

Result: negative

WIL2-NS HPRT/ t-Thioguanidine - Human B-Cell

lymphoblastoid, Literature data

Result: positive

Carcinogenicity

Not classifiable as to carcinogenicity to humans. Carcinogenic effects are not expected as a result of occupational exposure.

^{*} Estimates for product may be based on additional component data not shown.

Carcinogenicity

LITHIUM CARBONATE 0.02 mmol/L, NOAEL

Species: Rat

Notes: Literature Reference
TITANIUM DIOXIDE 0.5 mg/m3, Literature data

Result: negative Species: Rat

Test Duration: 24 months

0.72 - 14.8 mg/m3, Literature data

Result: negative Species: Mouse

10 - 250 mg/m3, Dietary study - Literature data.

Result: Inflammation at all doses with alveolar/bronchiolar

adenoma at the highest concentration.

Species: Rat

Test Duration: 24 months 25000 - 50000 ppm, Dietary study

Result: negative Species: Mouse

25000 - 50000 ppm, Dietary study - Literature data.

Result: negative Species: Rat

7.2 - 14.8 mg/m3, Literature data

Result: Lung tumour Species: Rat

Test Duration: 24 months

IARC Monographs. Overall Evaluation of Carcinogenicity

POVIDONE 30 (CAS 9003-39-8) Titanium dioxide (CAS 13463-67-7) 3 Not classifiable as to carcinogenicity to humans.

2B Possibly carcinogenic to humans.

Reproductive toxicity Components in this product have been shown to cause birth defects and reproductive disorders in

laboratory animals. These effects are linked only to high doses of this substance; low doses did

not produce this adverse effect.

Reproductivity

LITHIUM CARBONATE

10 - 200 mg/kg/day Reproduction/Fertility Study Result: Reduced reproductive capacity, increased pup mortality and delayed post-natal development.

Species: Mouse

Notes: Literature Reference

2 mg/kg/day Fertility, Male, Possibly species-specific.

Result: Inhibition of spermatogenesis.

Species: Rat

Notes: Literature Reference

Clinical use

Result: Cardiovascular malformations.

Species: Human

Notes: Literature Reference

Specific target organ toxicity -

single exposure

sure

Central nervous system.

LITHIUM CARBONATE Organ: Central nervous system.

Notes: Literature Reference

Specific target organ toxicity -

repeated exposure

Kidneys.

LITHIUM CARBONATE

Organ: Kidney

Notes: Literature Reference

Aspiration hazard

Not likely, due to the form of the product.

Mixture versus substance information

04 16 4

No information available.

Other information Caution - Pharmaceutical agent. Occupational exposure to the substance or mixture may cause

adverse effects.

SECTION 12: Ecological information

12.1. Toxicity Not expected to be harmful to aquatic organisms.

Components Species Test results

LITHIUM CARBONATE (CAS 554-13-2)

Aquatic

Acute

Crustacea EC50 Water flea (Daphnia magna) 1.2 mg/l, 48 hours Static test

Material name: LISKONUM TABLETS
4365 Version #: 14 Revision date: 04-November-2014 Issue date: 04-November-2014

Compor	nents		Species	Test results	
	Fish	EC50	Rainbow trout (Adult Oncorhyncus mykiss)	9.3 mg/l, 28 days Static renewal test	
POVIDONE 30 (CAS 9003-39-8)					
	Acute				
		IC50	Activated sludge	> 1000 mg/l, 3 hours Static test	
	Aquatic				
	Acute				
	Crustacea	EC50	Water flea (Daphnia magna)	84 mg/l, 48 hours Static test	
		NOEC	Water flea (Daphnia magna)	32 mg/l, 48 hours Static test	
Talc (CA	S 14807-96-6)				
	Aquatic				
	Acute				
	Fish	EC50	Zebra fish (Adult Brachydanio rerio)	> 100 g/l, 24 hours Static renewal test	
Titanium dioxide (CAS 13463-67-7)					
	Aquatic				
	Acute				
	Crustacea	EC50	Water flea (Daphnia magna)	> 1000 mg/l, 48 hours Static test	

^{*} Estimates for product may be based on additional component data not shown.

12.2. Persistence and degradability

Biodegradability

Percent degradation (Aerobic biodegradation-inherent)

POVIDONE 30 0 %, 28 days Modified MITI test, Activated sludge

12.3. Bioaccumulative potential No data available.

Partition coefficient

n-octanol/water (log Kow)

Not available.

12.4. Mobility in soil Not available. Not available. Mobility in general Not available. 12.5. Results of PBT

and vPvB assessment

12.6. Other adverse effects Not available.

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Residual waste Dispose of in accordance with local regulations. Empty containers or liners may retain some

product residues. This material and its container must be disposed of in a safe manner (see:

Disposal instructions). Avoid discharge into water courses or onto the ground.

Contaminated packaging Empty containers should be taken to an approved waste handling site for recycling or disposal.

Since emptied containers may retain product residue, follow label warnings even after container is

emptied.

EU waste code The Waste code should be assigned in discussion between the user, the producer and the waste

disposal company.

Collect and reclaim or dispose in sealed containers at licensed waste disposal site. Do not Disposal methods/information

discharge into drains, water courses or onto the ground. Dispose in accordance with all applicable

regulations.

Dispose in accordance with all applicable regulations. **Special precautions**

SECTION 14: Transport information

ADR

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

14.7. Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code

MARPOL Annex II applies to liquids used in a ship's operation that pose a threat to the marine

environment. These materials may not be transported in bulk.

Material name: LISKONUM TABLETS

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

EU regulations

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex I

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex II

Regulation (EC) No. 850/2004 On persistent organic pollutants, Annex I as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 1 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 2 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 3 as amended

Not listed

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex V as amended

Regulation (EC) No. 166/2006 Annex II Pollutant Release and Transfer Registry

Not listed.

Regulation (EC) No. 1907/2006, REACH Article 59(10) Candidate List as currently published by ECHA

Not listed.

Authorisations

Regulation (EC) No. 1907/2006, REACH Annex XIV Substances subject to authorization, as amended

Not listed.

Restrictions on use

Regulation (EC) No. 1907/2006, REACH Annex XVII Substances subject to restriction on marketing and use as amended

Directive 2004/37/EC: on the protection of workers from the risks related to exposure to carcinogens and mutagens at work

Not listed.

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breastfeeding

Not listed.

Other EU regulations

Directive 96/82/EC (Seveso II) on the control of major-accident hazards involving dangerous substances

Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work Not listed.

Directive 94/33/EC on the protection of young people at work

Not listed.

Other regulations The product is classified and labelled in accordance with EC directives or respective national laws.

This Safety Data Sheet complies with the requirements of Regulation (EC) No 1907/2006.

Young people under 18 years old are not allowed to work with this product according to the EU **National regulations**

Directive 94/33/EC on the protection of young people at work. Follow national regulation for work

with chemical agents.

15.2. Chemical safety

assessment

No Chemical Safety Assessment has been carried out.

SECTION 16: Other information

List of abbreviations Not available.

References **GSK Hazard Determination**

Information on evaluation method leading to the classification of mixture

The classification for health and environmental hazards is derived by a combination of calculation methods and test data, if available.

Full text of any statements or R-phrases and H-statements

under Sections 2 to 15 R22 Harmful if swallowed.

R36 Irritating to eyes.

R52/53 Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic

environment.

Material name: LISKONUM TABLETS

R61 May cause harm to the unborn child.

R64 May cause harm to breastfed babies.

H302 Harmful if swallowed.

H319 Causes serious eye irritation. H335 May cause respiratory irritation.

H360FD May damage fertility. May damage the unborn child.

H412 Harmful to aquatic life with long lasting effects.

Revision information Product and Company Identification: Product and Company Identification

Composition / Information on Ingredients: Undisclosed Ingredient Statement

Physical & Chemical Properties: Toxicological Information: Ecological information:

Transport Information: Material Transportation Information

Regulatory Information: Risk Phrases - Class.

GHS: Classification

Training information

Follow training instructions when handling this material.

Disclaimer

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Material name: LISKONUM TABLETS

SDS UK 10 / 10